Patents expiring in 2029

US 7510726

Methods and compositions for deterring abuse of opioid containing dosage forms

Acurx Pharmaceuticals, Inc. · Granted Tue Mar 31 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 26 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

EP 2041112

NEUE PYRIDINANALOGA

ASTRAZENECA AB [SE] · Granted Wed Apr 01 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Mar 27 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

EP 2041176

ANTIKÖRPERMOLEKÜLE FÜR HUMANES IL-17

ASTRAZENECA AB [SE] · Granted Wed Apr 01 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Mar 27 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

EP 2041135

ALS MODULATOREN VON TLR7 WIRKENDE 8-OXOADENINDERIVATE

ASTRAZENECA AB [SE] · Granted Wed Apr 01 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Mar 27 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7514467

Crystalline solids of carvedilol and processes for their preparation

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7514558

Biphenyl derivatives

Theravance, Inc. · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7514529

Peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccines

The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7514441

Substituted pyrazolo [1,5-A]pyrimidines as calcium receptor modulating agents

Takeda Pharmaceutical Company Limited · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7514434

Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof

Rigel Pharmaceuticals, Inc. · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7514414

Suppressors of CpG oligonucleotides and methods of use

The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7514095

Fabrication of drug loaded biodegradable polymer fibers

The Board of Regents of the University of Texas System · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7514096

Triacylglycerols of enriched CLA content

Aker Biomarine AS · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7514415

Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides

The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7514410

Hepatitis C therapies

BioCryst Pharmaceuticals, Inc. · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7514425

Short-acting sedative hypnotic agents for anesthesia and sedation

Theravance, Inc. · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7514436

Pyridazine derivatives and their use as therapeutic agents

Xenon Pharmaceuticals Inc. · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7514448

Azaindoles useful as inhibitors of rock and other protein kinases

Vertex Pharmaceuticals Incorporated · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

AR 064495

DERIVADOS DE PIPERIDIN-CARBONILFENIL SULFONAMIDAS

ASTRAZENECA AB [SE] · Granted Wed Apr 08 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Apr 03 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

EP 2044019

3-OXOISOINDOLIN-1-CARBONSÄUREAMIDDERIVATE ALS ANALGETIKA

ASTRAZENECA AB [SE] · Granted Wed Apr 08 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Apr 03 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

EP 2044050

NEUE PYRIDINANALOGA

ASTRAZENECA AB [SE] · Granted Wed Apr 08 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Apr 03 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

EP 2044063

FÜR DIE BEHANDLUNG VON KREBS GEEIGNETE PYRIMIDINDERIVATE

ASTRAZENECA AB [SE] · Granted Wed Apr 08 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Apr 03 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7517895

Synthetic diazonamides

The Board of Regents of the University of Texas System · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7517971

Muteins of human telomerase reverse transcriptase lacking telomerase catalytic activity

The Regents of the University of Colorado · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7517886

Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

Rigel Pharmaceuticals, Inc. · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7517527

Immunotoxin with in vivo T cell suppressant activity and methods of use

The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7517865

RNAi modulation of RSV and therapeutic uses thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7517858

Prodrugs of pharmaceuticals with improved bioavailability

The Regents of the University of California · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7517661

Methods of screening for ligands for FPRL2

Takeda Pharmaceutical Company Limited · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7517849

Inhibition of ABC transporters by transmembrane domain analogs

The United States of America, as represented by the Secretary, Health and Human Services · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7517531

Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4

The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7517871

Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders

ACADIA Pharmaceuticals Inc. · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7517910

Alkoxyphenylpropanoic acid derivatives

Takeda Pharmaceutical Company Limited · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7517987

Caspase inhibitors and uses thereof

Vertex Pharmaceuticals Incorporated · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

EP 2046782

IMIDAZOLYLPYRIMIDINDERIVATE ZUR BEHANDLUNG VON MIT GLYKOGENSYNTHASEKINASE (GSK3) IN ZUSAMMENHANG STEHENDEN KRANKHEITEN

ASTRAZENECA AB [SE] · Granted Wed Apr 15 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Apr 10 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7521175

Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571

The Regents of the University of California · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7521063

Multiple CPG oligodeoxynucleotides and their use to induce an immune response

The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7521054

Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the Fv to lower the isoelectric point

The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7521561

Biphenyl derivatives

Theravance, Inc. · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7521049

Use of VEGF inhibitors for treatment of eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7521041

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7521418

Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent

Theravance, Inc. · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7521558

Crystalline form of a biphenyl compound

Theravance, Inc. · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7521211

IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7521551

Chlorins possessing fused ring systems useful as photoselective compounds for photodynamic therapy

Miravant Pharmaceuticals, Inc. · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7521192

EDG: modulators of lymphocyte activation and migration

Rigel Pharmaceuticals, Inc. · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7521414

Polyol macrolide antitumor-antibiotics from the marine actinomycete strain CNQ140

The Regents of the University of California · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7521475

Chondropsin-class antitumor V-ATPase inhibitor compounds, compositions and methods of use thereof

The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7521535

Anti-microbial defensin-related peptides and methods of use

The Board of Regents for Oklahoma State University · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)